Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 2, 2011, Pages 256-263

  Raman, Bhanu ^a   Sharma, Brajesh A ^a,b   Mahale, Ganesh ^b   Singh, Dharmendra ^b   Kumar, Ashok ^b  

^a K J Somaiya College of Science and Commerce   (India)

^b Ipca Laboratories Ltd   (India)

Author keywords

Candesartan cilexetil; Impurities; LC ESI ITMS; NMR; Transesterification

Indexed keywords

2 ETHOXY 1 [(2' (1 ETHYL 1H TETRAZOL 5 YL)BIPHENYL 4 YL)METHYL] 1H BENZIMIDAZOLE 7 CARBOXYLIC ACID ETHYL ESTER; CANDESARTAN HEXETIL; UNCLASSIFIED DRUG;

ARTICLE; DRUG IMPURITY; DRUG ISOLATION; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION TRAP MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITIVE ION ELECTROSPRAY; PRIORITY JOURNAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; DRUG COMPOUNDING; DRUG CONTAMINATION; ESTERIFICATION; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; QUALITY CONTROL; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; TECHNOLOGY, PHARMACEUTICAL; TETRAZOLES;

EID: 79960045140     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.05.024     Document Type: Article

References (12)

1. ICH Q3A (R2) Guideline, Impurities in New Drug Substances (version 4), 2006.
2. Dongre V.G., Karmuse P.P., Ghugare P.D., Kanojiya S.K., Rawal S. Investigation of amodiaquine bulk drug impurities by liquid chromatography/ion trap mass spectrometry. Rapid Commun. Mass Spectrom. 2008, 22:1-7.
3. Martindale - The Complete Drug Reference 2009, 1238-1239. Pharmaceutical Press, London. 36th ed. S.C. Sweetman (Ed.).
4. M.Y. Etinger, V. Niddam-Hildesheim, B. Fedotev, B. Dolitzky, WO Patent 2005/111021 A1 (November 2005).
5. Stenhoff H., Lagerstrom P., Andersen C. Determination of candesartan cilexetil, candesartan and metabolite in human plasma and urine by liquid chromatography and fluorometric detection. J. Chromatogr. B 1999, 731:411-417.
6. Ferreiros N., Dresen S., Alonso R.M., Weinmann W. Hydrolysis and transesterification reactions of candesartan cilexetil observed during the solid phase extraction procedure. J. Chromatogr. B 2007, 855:134-138.
7. Rao D.V.S., Radhakrishnanand P., Suryanarayana M.V., Himbindu V. A stability-indicating LC method for candesartan cilexetil. Chromatographia 2007, 66:499-507.
8. Mohan A., Shanmugavel S., Goyal A., Venkataraman B.R., Sarvanan D. Identification, isolation, and characterization of five potential degradation impurities in candesartan cilexetil tablets. Chromatographia 2009, 69:1-10.
9. Mehta S, Shah R.P., Priyadarshi R., Singh S. LC and LC/TOF studies on stress degradation behaviour of candesartan cilexetil. J. Pharm. Biomed. Anal. 2010, 52:345-354.
10. Havlicek J., Mandelova Z., Weisemann R., Strelec I., Placek L., Radl S. Identification, synthesis and structural determination of some impurities of candesartan cilexetil. Collct. Czech. Chem. Commun. 2009, 74:347-362.
11. S.Z. Zupnca, United States Patent 2010/0197933 A1 (August 2010).
12. Irwin W.J., Masuda Q.N., Po A.L.W. Transesterification kinetics of phenyl salicylate. Tetrahedron 1984, 40:3217-5223.